Merck is in discussions with various global health authorities about making its COVID antiviral pill molnupiravir ‌available ...

An at-home pill against coronavirus halves the chance that people newly diagnosed with COVID-19 will land in the hospital or ...

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that data evaluating LAGEVRIO™ ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that LAGEVRIO™ (molnupiravir) did not demonstrate a statistically significant ...

A new study published Monday links COVID-19 antiviral created by Merck with new mutations of the virus that have been sequenced around the world. Molnupiravir, known commercially as Lagevrio, is one ...

The U.S. government will stop distributing free doses of Merck & Co's COVID-19 antiviral treatment molnupiravir by the middle of next month and expects it to be sold on the commercial market instead.

Weighing three outpatient treatments for COVID-19, the drug cost watchdog Institute for Clinical and Economic Review (ICER) has determined that Pfizer’s Paxlovid, Merck and Ridgeback Biotherapeutics’ ...

The Medicines Patent Pool on Jan. 20 said it had signed agreements with 27 generic drugmakers to manufacture molnupiravir — Merck’s COVID-19 antiviral — to advance accessibility in 105 developing ...

The World Health Organization has recommended Merck’s molnupiravir to treat high-risk Covid patients, the agency announced Thursday, the first oral antiviral it has endorsed though availability is ...